ArticleJTO clinical and research reports2026
Paraneoplastic Brachial Amyotrophic Diplegia and Encephalitis With Ma2-IgG During Immune Checkpoint Inhibitor Use for Mesothelioma: A Case Report.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) improve cancer survival but can cause neurologic immune-related adverse events. Ma2-IgG-associated paraneoplastic neurologic syndrome typically presents with central nervous system involvement in patients with testicular or lung cancers. We present a case of paraneoplastic brachial amyotrophic diplegia (BAD) associated with Ma2-IgG which developed after ICI. Case Report: This is a case report of an 86-year-old man with pleural mesothelioma treated with nivolumab and ipilimumab, who presented with progressive, asymmetric weakness of his upper extremities after 5 cycles of ICI. Examination did not reveal associated sensory deficits. Blood creatine kinase level was normal and acetylcholine receptor antibody testing result was negative. Magnetic resonance imaging revealed findings consistent with bilateral frontal temporal lobe encephalitis, but without concurrent cervical cord lesions. Cerebrospinal fluid analysis revealed mild pleocytosis and oligoclonal bands. Ma2-IgG was present in the cerebrospinal fluid (>1:32) and serum (>1:3200). Electrodiagnostic testing revealed diffuse chronic innervation and active denervation changes involving the upper extremities raising concern for a motor neuron disorder. He was diagnosed with having paraneoplastic BAD and encephalitis. A progressive course ensued, despite initial transient improvement with escalation of immunosuppression. Conclusion: Paraneoplastic BAD is an uncommon paraneoplastic phenomenon that can occur with Ma2-IgG in the setting of ICI use and atypical tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.